COPERNICO

A RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB COMBINED WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)-PNEUMONIA WHO ARE UNRESPONSIVE TO STANDARD CARE 

PROJECT DETAILS

COPERNICO PRIMARY OBJECTIVE IS TO ASSESS THE EFFICACY–AS DETERMINED BY THE PROPORTION OF PATIENTS WITH NORMALIZATION OF SPO2 ≥96%– OF CONTINUED STANDARD CARE TOGETHER WITH TOCILIZUMAB PLUS PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH COVID-19 PNEUMONIA WHO ARE NONRESPONSIVE TO FRONTLINE THERAPY WITHIN 48 HOURS FROM TREATMENT INITIATION.  IS A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO-ARM, PHASE II CLINICAL TRIAL IN MEN WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC). 

EXPLORATORY OBJECTIVE IS TO ESTABLISH WHETHER STUDY TREATMENT WOULD ALLOW TO RECOVER T CELL FUNCTIONALITY AND REGULATE CYTOKINE STORM IN PATIENTS WITH COVID- 19 PNEUMONIA WHO ARE NONRESPONSIVE TO FRONTLINE THERAPY WITHIN 48 HOURS FROM TREATMENT INITIATION. 

COPERNICO AT CLINICALTRIALS.GOV

N

SITES

COUNTRY

STATUS

24

6

Spain

Recruiting

COPERNICO SITES

SPAIN

Hospital Arnau de Vilanova de Valencia

SPAIN

Hospital Universitario Dr Peset

SPAIN

Hospital Quirónsalud Barcelona

SPAIN

Hospital Ruber Internacional 

SPAIN

Hospital Ruber Juan Bravo